[ad_1]
law firm Kessler Topaz Meltzer & Check, LLP Investors are notified that a securities class action lawsuit has been filed against Talis Biomedical Corporation (“Talis”) (("http://www.w3.org/1999/xhtml" Relative ="Not concerned" link="https://cts.businesswire.com/ct/CT?id=smartlink&, url=https%3A%2F%2Fwww.marketwatch.com%2Finvesting%2Fstock%2Ftlis%3Fmod%3Dover_search&, esheet=52563468&, newsitemid =20220116005019&, lan=en-US&, anchor=NASDAQ%3A+TLIS&, index=2&, NASDAQ:TLIS). The lawsuit charges Talis with violations of federal securities laws, including omissions and fraudulent misrepresentation about the company’s business, operations and prospects. Investors in Talis have suffered significant losses as a result of Talis making materially misleading statements to the public.
watch our video please click here
click here Submit your TALIS loss
Lead Plaintiff Deadline: March 8, 2022
Class time: February 12, 2021 to January 7, 2022
Contact a lawyer to discuss your rights:
James Marrow, Esq. (484) 270-1453 or toll free (844) 887-9500 or email at info@ktmc.com
Very important’ alleged misconduct
Talis develops diagnostic tests to enable accurate, reliable, low-cost and rapid molecular testing for infectious diseases. Specifically, Talis One is developing tests for respiratory infections, women’s health-related infections, and sexually transmitted infections. Talis disclosed in its registration statement that in January 2021, the company submitted an Emergency Use Authorization (“EUA”) request to the U.S. Food and Drug Administration (“FDA”) for its Talis One platform for COVID-19 testing -19 test.
Then, on March 8, 2021, Talis announced…
The full story is available on Benzinga.com
[ad_2]
Source link
